We are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms.
Triple-negative breast cancer, a hard-to-treat cancer subtype more common in young women, needs improved drugs to increase patient survival. Our innovation, a small molecule that targets G-quadruplex DNA structures, will selectively eradicate triple-negative breast cancer cells, and thereby improve treatment.
Fibrotic disorders are an increasing cause of morbidity and mortality worldwide contributing to approx. 45% of deaths in the developed world. A major cause of liver fibrosis is NASH, a severe form of the metabolic condition non-alcoholic fatty liver disease (NAFLD).
NanoBio Select@ is developing novel highly sensitive detection devices with aims to improve immunoassay technologies.
